-

10:30:59 AM

SLRX Stock News

SLRX - Salarius Pharmaceuticals Inc

08/04/22 8:30 AM

Nasdaq : SLRX

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the addition of

RHEA-AI

neutral

08/02/22 8:30 AM

Nasdaq : SLRX

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company,

RHEA-AI

very positive

07/29/22 9:15 AM

Nasdaq : SLRX

conferencesearnings

Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that

RHEA-AI

neutral

06/09/22 7:33 AM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will participate in the 2022 BIO International

RHEA-AI

neutral

05/18/22 4:10 PM

Nasdaq : SLRX

conferences

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other solid and hematological cancers, today announced that David Arthur, CEO

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : SLRX

earnings

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible LSD1 inhibitor Multiple potential development and data

RHEA-AI

positive

05/11/22 4:05 PM

Nasdaq : SLRX

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, hematologic

RHEA-AI

neutral

05/05/22 7:30 AM

Nasdaq : SLRX

conferencesearnings

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options,

RHEA-AI

neutral

04/22/22 8:30 AM

Nasdaq : SLRX

offering

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has entered into definitive agreements with several

RHEA-AI

neutral

03/10/22 4:05 PM

Nasdaq : SLRX

earnings

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing with updates from two Phase 1/2 clinical trials in sarcoma and hematologic cancer patients

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

SLRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitesalariuspharma.com
CeoDavid Arthur
Security nameSalarius Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees8
Tags
- Health Technology
- Pharmaceuticals: Other
- Commercial Services
- Miscellaneous Commercial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2450 Holcombe Blvd Ste J-608
StateTexas
CityHouston
Zip77021-2041
CountryUS
Phone13467720346

About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).